Access and Evidence
Indian Court Shows Concern Over Clinical Trial Practices
The Indian Supreme Court has expressed concern over the failure of regulators to curb illegal and dangerous clinical trials said to be causing “havoc” in the country.
More Access and Evidence Articles
Access and Evidence
Business Nonsense: Why the Pharmaceutical Industry is Crippled by a Bad Business Model and How to Fix It
With spiralling clinical trial costs, pharma companies are looking for savings. But less money spent is not necessarily money better spent.
Access and Evidence
Big Data: A Big Opportunity for 2013
Big data became a priority in 2012 as companies found themselves with a lot of raw information but little analysis or the right tools to manage the data.
Access and Evidence
NICE Can See Clearly Now the Price has Gone
The National Institute for Health and Clinical Excellence (NICE) has recommended Lucentis as an option to treat diabetes-related vision problems following a cut-rate offer by the drug manufacturer to the National Health Service (NHS).
Access and Evidence
NHS to Target Unnecessary Prescription of Branded Drugs
The NHS has announced a plan to target the unnecessary prescription of branded drugs by GPs in an attempt to reduce its annual £8bn family medicine bill.
Access and Evidence
A Paradigm Shift in Personalized Medication
Personalized medication remains a hot topic in the pharma industry so it is important that we get the freshest insight regarding the role it plays at present, and what effects said role will have on the immediate future.
Access and Evidence
Cell-Based System Provides New Way to Screen Drugs for Cardiaotoxicity
Scientists have developed a new cell-based system for screening experimental drugs that could help with early identification of cardiotoxic side effects.
Access and Evidence
A Mixed Bag of Results – Assessing R&D in the Pharma Industry for 2012
More and more evidence has come to light that R&D in the pharma industry is becoming increasingly and alarmingly expensive.
Access and Evidence
Essential Drug Prices Capped in India
A price capping policy set to be implemented will effect 30% of all drugs sold in the Indian healthcare market.
Access and Evidence
Unified European Patent System Brings Relief for Pharma Companies
A paradigm shift for the cumbersome lodging of patents in Europe took place yesterday, with the long awaited agreement of a unified patent system for the European Union (EU) finally ratified.